Skip to main content
Equibles
CVSA logo

CVSA · Covista Inc.

Track CVSA — free

Use CVSA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CVSA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$134.63 -6.05 (-4.30%) At close · Aug 28
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.75B
Shares
34.04M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$140.68 Open$137.18 Day$137.16–141.43 52W close$89.36–154.45 Avg vol 30d346K Short int1.6M · 4.8% float · 4.5d Short vol65% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-K · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 10 wks
FQ1-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-K
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +24%
      above
      Price vs 50-day avg +11%
      above
      RSI (14) 63
      neutral
      MACD trend Positive
      52-week position 79%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +11%
      trailing
      6-month return +38%
      trailing
      YTD return +36%
      this year
      Relative strength +23%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $127 › 200d $114 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +56 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.79% of float · ▼ -1.3% MoM · 4.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      374 holders — mid 3-yr range
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +9%
      Y/Y
      EPS growth +14%
      Y/Y
      Free cash flow $392.7M
      Valuation P/E 19.8
      in line
      Buyback $661.8M
      remaining
      Quant / Vol
      risk profile
      Very High
      Volatility 53%
      annualized · 1-yr
      Max drawdown −42%
      past year
      ATR 4.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Prior guidance period ended · from the Earnings Call filed Dec 31, 2025
      Full-year revenue growth · full-year 6% – 8.5%
      Adjusted earnings per share growth · full-year 17% – 20%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +24% Bullish
      Price vs 50-day avg
      +11% Bullish
      RSI (14)
      63 Neutral
      MACD trend
      Positive Bullish
      52-week position
      79% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $127 › 200d $114 — 50d above 200d
      Institutional flow Accumulating
      +5% holders QoQ · +56 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      4.79% of float · ▼ -1.3% MoM · 4.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      374 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $89 Now $141 · 79% Range high $154
      vs 200-day avg +24% vs 50-day avg +11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA (non-GAAP) non-GAAP $521.74M Year Ended June 30, 2026 —
      Adjusted net income (non-GAAP) non-GAAP $294.7M Year Ended June 30, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net income (GAAP) 251.57M
      +6.33M Restructuring expense
      +11.22M Amortization of acquired intangible assets
      +18.56M Strategic advisory costs
      +4.81M Loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, and debt modification costs
      -3.29M Tax benefit due to change in unrecognized tax benefits
      -10.31M Income tax impact on non-GAAP adjustments
      +15.81M Loss (income) from discontinued operations
      = Adjusted net income (non-GAAP) 294.7M
      Adjusted operating income (Chamberlain) non-GAAP $143.64M Year Ended June 30, 2026 filing —
      Adjusted operating income (Medical and Veterinary) non-GAAP $79.97M Year Ended June 30, 2026 filing —
      Adjusted operating income (non-GAAP) non-GAAP $419.49M Year Ended June 30, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Operating income (GAAP) 383.38M
      +6.33M Restructuring expense
      +11.22M Amortization of acquired intangible assets
      -5.55M Litigation reserve
      +6.44M Asset impairments
      +18.56M Strategic advisory costs
      -490K Loss on assets held for sale
      -712K Debt modification costs
      = Adjusted operating income (non-GAAP) 419.49M
      Adjusted operating income (Walden) non-GAAP $239.72M Year Ended June 30, 2026 filing —
      Adjusted operating margin (non-GAAP) non-GAAP 21.5% Year Ended June 30, 2026 —
      Free cash flow (non-GAAP) non-GAAP $393.1M Q4 FY2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net cash provided by operating activities-continuing operations (GAAP) $470.8M
      -$77.7M Capital expenditures
      = Free cash flow (non-GAAP) $393.1M
      Medical and Veterinary enrolled students (average) 5,250 fiscal year —
      Net debt (non-GAAP) non-GAAP $266.68M Year Ended June 30, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Total long-term debt principal $673M
      -$406.32M Less: Cash and cash equivalents
      = Net debt (non-GAAP) $266.68M
      Total segment adjusted operating income non-GAAP $463.33M Year Ended June 30, 2026 filing —
      Adjusted EBITDA (Chamberlain) non-GAAP $138.76M Nine Months Ended March 31, 2026 —
      Adjusted EBITDA (Covista) non-GAAP $394.82M Nine Months Ended March 31, 2026 —
      Adjusted EBITDA (Home Office) non-GAAP -$22.53M Nine Months Ended March 31, 2026 —
      Adjusted EBITDA (Medical and Veterinary) non-GAAP $80.3M Nine Months Ended March 31, 2026 —
      Adjusted EBITDA (Walden) non-GAAP $198.29M Nine Months Ended March 31, 2026 —
      Adjusted EBITDA margin (Covista) non-GAAP 27.2% Nine Months Ended March 31, 2026 —
      Adjusted EBITDA margin (Medical and Veterinary) non-GAAP 26.9% Nine Months Ended March 31, 2026 —
      Net leverage (Covista) non-GAAP 0.7 Twelve Months Ended March 31, 2026 —
      Net leverage 0.9 Q2 FY2026 —
      Total student enrollment 97,010 Q2 FY2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Education & Training Services — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CVSA
      Covista Inc.
      this stock
      		$4.75B +36.0% +9.3% 19.8 4.8%
      EDU
      New Oriental Education & Technology Group Inc.
      		 $9.26B +5.3% +13.6% — 1.9%
      TAL
      TAL Education Group
      		 $6.57B +7.4% +33.7% — 3.7%
      LAUR
      Laureate Education, Inc.
      		 $5.38B +15.9% +19.5% 17.8 2.4%
      LOPE
      Grand Canyon Education, Inc.
      		 $3.91B -9.7% +19.8% 18.2 6.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      374
      % held
      100.9%
      Net QoQ
      -182.0K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      376
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      1.6M
      Days to cover
      4.5d
      Change
      -21.5K sh
      View
      Short Volume
      Short vol %
      65%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      3
      Value
      $345
      As of
      Jul 24, 2026
      View
      Off-Exchange
      Off-exchange %
      42.1%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $2.0B
      Net income (FY)
      $251.6M
      EPS diluted
      $7.04
      View
      Buybacks
      Authorized
      $750.0M
      Remaining
      $661.8M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $248.3K
      Shares
      1.8K
      Filed
      Aug 27, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CVSA +9.9% +11.3% +37.9% +12.7% +36.0%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY +8.8% +7.3% +23.2% +9.5% +22.9%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $750.00M
      Spent (derived)
      $88.20M
      Remaining
      $661.80M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 730464 CUSIP 00737L103 13F (30d) 302 filings 300 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)